Affichem is a biotechnology company which develops a portfolio of small molecules with strong therapeutic potential: the Dendrogenins.

Created in October 2002, this innovative Company is located in Toulouse which hosts the largest University Cancer Institute in Europe.

Based on the results of many years of academic research, this spin-off of INSERM is now developing compounds belonging to the Dendrogenins’ family in three distinct major markets: cancer (including acute myeloid leukemia, melanoma, breast cancer) , neurodegenerative diseases (including deafness and hearing loss), and dermo-cosmetics (including self-tanning, anti-aging).

The first two families of proprietary molecules selected by Affichem target the markets whose needs are significant and unmet: acute myeloid leukemia (AML), metastatic melanoma and refractory breast cancers (AF122) and hearing loss and deafness (AF243). The third family of proprietary molecules targets the cosmetics market (AF130).

Affichem is also targeting the diagnostic market with the discovery of a breast cancer biomarker for the detection and monitoring of therapeutic efficacy of anti-cancer drugs (AF300).
This biomarker, intended for commercialization but also for the optimization of internal clinical research, involves Affichem in the field of theranostics.

The company aims to develop drug candidates, biomarkers and compounds until their transfer to the pharmaceutical industry or the dermo-cosmetic industry which will ensure the end of developments and marketing of its products.

Biomarker - Cancer - Deafness - Melanoma - Neurodegenerative disease - Theranostic - Diagnosis - Prognosis - Drug design - Anticancer therapy - Cell differentiation - Receptor - Enzyme - Metabolism - Medicinal chemistry - Biotechnology - First in class molecule - New Chemical Entities - Cholesterol - Tamoxifen - Immunotherapy - Exosome - Oncology - Dendritic cell -